755 related articles for article (PubMed ID: 34946543)
1. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
Yapasert R; Khaw-On P; Banjerdpongchai R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Malekmohammad K; Rafieian-Kopaei M
Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
[TBL] [Abstract][Full Text] [Related]
3. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
4. Effective inhibition of coronavirus replication by
Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
[No Abstract] [Full Text] [Related]
5. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
6.
Umadevi P; Manivannan S; Fayad AM; Shelvy S
J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
[No Abstract] [Full Text] [Related]
7. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
8. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
9. Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs.
Merarchi M; Dudha N; Das BC; Garg M
Phytother Res; 2021 Oct; 35(10):5384-5396. PubMed ID: 34132421
[TBL] [Abstract][Full Text] [Related]
10. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
Viruses; 2022 May; 14(5):. PubMed ID: 35632703
[TBL] [Abstract][Full Text] [Related]
12. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
13. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
[TBL] [Abstract][Full Text] [Related]
14. Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*.
Gil-Moles M; Basu U; Büssing R; Hoffmeister H; Türck S; Varchmin A; Ott I
Chemistry; 2020 Nov; 26(66):15140-15144. PubMed ID: 32915473
[TBL] [Abstract][Full Text] [Related]
15. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
16. Flavonol morin targets host ACE2, IMP-α, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis.
Gupta A; Ahmad R; Siddiqui S; Yadav K; Srivastava A; Trivedi A; Ahmad B; Khan MA; Shrivastava AK; Singh GK
J Biomol Struct Dyn; 2022 Aug; 40(12):5515-5546. PubMed ID: 33526003
[TBL] [Abstract][Full Text] [Related]
17. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
Xu G; Li Y; Zhang S; Peng H; Wang Y; Li D; Jin T; He Z; Tong Y; Qi C; Wu G; Dong K; Gou J; Liu Y; Xiao T; Qu J; Li L; Liu L; Zhao P; Zhang Z; Yuan J
Cell Res; 2021 Dec; 31(12):1230-1243. PubMed ID: 34663909
[TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
